HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development ...

SSC Phase 13 Answer Key 2025 : SSC Selection Post Answer Key 2025 is likely to be released soon by the Staff Selection Commission. The SSC Selection Post Phase 13 Answer Key 2025 which is generally ...

Co-CEO Bob Duggan highlighted significant progress with ivonescimab, Summit Therapeutics' lead investigational asset, emphasizing its potential impact on unmet medical needs. Key milestones included ...

Nektar Therapeutics has two Phase IIb studies underway for rezpeg in atopic dermatitis and severe alopecia areata, with read-outs expected in 1H'25. Success in either indication would significantly ...

GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...

Cytokinetics' share price surged on rumors of potential takeover interest from Novartis and AstraZeneca. The buyout of Myokardia shows how attractive an asset like aficamten can be, but the price tag ...

Takeda’s closely watched and highly valued dermatology pill zasocitinib has won out in two key phase 3 trials, giving the Japanese pharma confidence to move toward a 2026 approval filing in the U.S.

PERTH AMBOY — The second phase of a massive three-phase project to rebuild NJ Transit's Raritan River Bridge began on a sweltering Tuesday, June 24. "So many of the coastal towns, of which I live in ...